Monday, August 21, 2006
2006 Bevacizumab (Avastin) combination therapy in recurrent, platinum-refractory epithelial ovarian carcinoma: a retrospective analysis
Review:
Cancer. 2006 Jul 1;107(1):83-9.Click here to read Links
Bevacizumab combination therapy in recurrent, platinum-refractory epithelial ovarian carcinoma: A retrospective analysis.
* Wright JD,
* Hagemann A,
* Rader JS,
* Viviano D,
* Gibb RK,
* Norris L,
* Mutch DG,
* Powell MA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. wrightj@msnotes.wustl.edu
BACKGROUND: The study was undertaken to determine the safety and efficacy of the monoclonal, antivascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with platinum-refractory ovarian cancer.
METHODS: A retrospective analysis of women who received bevacizumab in combination with a cytotoxic agent was performed. Response was determined by measurable disease or assessment of serial cancer antigen (CA) 125 measurements.
RESULTS: Twenty-three patients were identified. The patients were heavily pretreated with a median of 7 prior regimens including a median of 3 prior platinum regimens. The combination regimen included cyclophosphamide in 15 (65%), 5-fluorouracil (5-FU) in 6 (26%), docetaxel in 1 (4%), and gemcitibine/liposomal doxorubicin in 1 (4%). Two (9%) women developed chylous ascites during treatment. CTC Grade 4-5 toxicities occurred in 4 (17%) subjects. Gastrointestinal perforation occurred in 2 (9%) patients. Measurable disease was present in 22. The overall best response rate was 35% and all 8 were partial responses (PRs). Stable disease was found in a further 10 (44%) women, whereas progressive disease was observed in 5 (22%). The median time to progression was 5.6 months in patients with a PR and 2.3 months in subjects with stable disease. Three (13%) women experienced a progression-free interval (PFI) of >6 months. At last follow-up, 8 (35%) subjects had died of disease, whereas 15 (65%) women were alive with disease.
CONCLUSIONS: Combination bevacizumab therapy demonstrated activity in heavily pretreated women with ovarian cancer. Gastrointestinal perforations were identified in 9%. Despite the toxicity of the regimen, prospective studies, particularly in less heavily pretreated patients, are warranted. Copyright 2006 American Cancer Society.
PMID: 16736514 [PubMed - indexed for MEDLINE]
Wednesday, July 26, 2006
Monday, July 24, 2006
2006 Whitby, Ontario - Ovarian Cancer Get Together
Letter of thanks to local business community on behalf of our ovarian cancer community:
Sandi Pniauskas
117 Glen Hill Drive
Whitby, Ontario, Canada L1N 6Z8
tel: 905 668-0767 fax: 905 666-0188
email: sandipn@sympatico.ca
Monday, July 24, 2006
Mr. Craig Gilpin
President
c/o Sobeys Canada
6355 Viscount Road
Mississauga, Ontario
L4V 1W2
Dear Mr. Gilpin:
Re: Ovarian Cancer Community, Whitby, Ont. July 22nd, 2006
On behalf of our ovarian cancer women/carers, may we express our thanks to Janet/Joe Glover (Oshawa); Nick Lucarelli/Tom Theodore (Whitby) and Alan Risk (Retail Stores, Ontario) for their generous donation(s). Your staff, as individuals and members of the community, recognized the significance of this unique event and the positive responses were sincerely appreciated.
Our unique ovarian cancer survivourship event was coordinated solely for and by survivours/carers. Participants included Canada, U.S., England and Australia. Given the success of our event, we have established a new ovarian cancer tradition. Both Chicago (2007) and Annapolis (2008) are now being organized and requests have been made for 2009. The profound sense of accomplishment in recognizing the power of the individual – the human connection was exceptional. Our positive experience with Sobeys staff confirms for us that you are well-represented in this area of human compassion and need.
Please accept and extend our thanks for recognizing and proactively supporting those in our ovarian cancer community(s).
Sincerely;
Sandi Pniauskas
Ovarian Cancer Survivour
cc: Alan Risk
Subscribe to:
Posts
(
Atom
)
